Future studies inhibiting NOX1 or blocking activation of UNC5C-cleaving caspases, or supplementing with Netrin1, to test their ability to ameliorate AD pathology and neurodegeneration, could potentially lead to new therapeutic agents for AD. The gene discussed is UNC5C; the disease is Alzheimer disease.